Sökning: onr:"swepub:oai:DiVA.org:mau-3919" > In Vivo Investigati...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 02985naa a2200409 4500 | |
001 | oai:DiVA.org:mau-3919 | |
003 | SwePub | |
008 | 200228s2010 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-39192 URI |
024 | 7 | a https://doi.org/10.1002/jps.219692 DOI |
040 | a (SwePub)mau | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Albrecht, Karin4 aut |
245 | 1 0 | a In Vivo Investigation of Thiomer-Polyvinylpyrrolidon Nanoparticles Using Magnetic Resonance Imaging |
264 | 1 | b Wiley Inter Science,c 2010 |
338 | a print2 rdacarrier | |
520 | a This study focused on the investigation of the permeation enhancing effects of a stomach targeted, nanoparticulate drug delivery system. The polyacrylic acid–cysteine/polyvinylpyrrolidon nanoparticles were loaded with the magnetic resonance imaging (MRI) contrast agent diethylenetriaminepentaacetic acid gadolinium( III)dihydrogen salt (Gd-DTPA). Average particle size was determined to be 130nm and the optimum for stability was found to be below a pH of 4.5. In vitro permeation studies were performed on rat gastric mucosa and revealed an eightfold increase in Gd- DTPA uptake when incorporated in the nanoparticles compared to evaluation in the presence of unformulated polyacrylic acid–cysteine. In vivo investigations with rats were performed via the noninvasive MRI method in order to track the nanoparticles way through the gastrointestinal tract. When Gd-DTPA was administered orally as nanoparticulate suspension, an increased MRI signal in the urinary bladder was detected after 34 min, providing evidence for systemic uptake and renal elimination of the contrast agent. As control experiments with Gd-DTPA only or in combination with unformulated polyacrylic acid–cysteine revealed no MRI signal increase at all, the significant permeation enhancing effect could be identified based on the nanoparticulate formulation. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a nanoparticles | |
653 | a oral drug delivery | |
653 | a absorption enhancer | |
653 | a polymeric drug delivery | |
700 | 1 | a Greindl, Melanie4 aut |
700 | 1 | a Deutel, Britta4 aut |
700 | 1 | a Kremser, Christian4 aut |
700 | 1 | a Wolf, Christian4 aut |
700 | 1 | a Talasz, Heribert4 aut |
700 | 1 | a Stollenwerk, Maria Magdalena,d 1959-4 aut |
700 | 1 | a Debbage, Paul4 aut |
700 | 1 | a Bernkop-Schnürch, Andreas4 aut |
773 | 0 | t Journal of Pharmaceutical Sciencesd : Wiley Inter Scienceg 99:4, s. 2008-2017q 99:4<2008-2017x 0022-3549x 1520-6017 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-3919 |
856 | 4 8 | u https://doi.org/10.1002/jps.21969 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy